Harmony Biosciences Holdings Inc (HRMY)

$32.53 +0.11 (0.34%)
Market Cap 1.86B
Revenue (ttm) 714.73M
Net Income (ttm) 145.49M
EPS (ttm) N/A
PE Ratio 13.29
Forward PE 11.56
Profit Margin 20.36%
Debt to Equity Ratio 0.27
Volume 591,300
Avg Vol 682,596
Day's Range N/A - N/A
Shares Out 57.35M
Stochastic %K 10%
Beta 0.80
Analysts Strong Sell
Price Target $49.50

Latest News on HRMY

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 19 hours ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect

Apr 1, 2025, 10:00 AM EDT - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation

Mar 31, 2025, 10:00 AM EDT - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation

Mar 30, 2025, 10:00 AM EDT - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to Connect

Mar 28, 2025, 10:00 AM EDT - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to Connect

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 6 days ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation

Mar 26, 2025, 10:00 AM EDT - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:05 AM EDT - 7 days ago

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation

Mar 25, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out

Mar 24, 2025, 2:00 PM EDT - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out

Harmony Biosciences: A Compelling Risk-Reward Opportunity

Mar 24, 2025, 12:09 PM EDT - 9 days ago

Harmony Biosciences: A Compelling Risk-Reward Opportunity

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

Mar 24, 2025, 8:05 AM EDT - 9 days ago

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

Mar 21, 2025, 7:45 PM EDT - 12 days ago

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

Harmony Biosciences to Participate in Upcoming Investor Conferences

Mar 4, 2025, 8:05 AM EST - 4 weeks ago

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 3:05 PM EST - 5 weeks ago

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2024 Earnings Call Transcript

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Feb 25, 2025, 7:30 AM EST - 5 weeks ago

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Feb 19, 2025, 2:24 PM EST - 6 weeks ago

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Feb 19, 2025, 8:05 AM EST - 6 weeks ago

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 18, 2025, 8:05 AM EST - 6 weeks ago

Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech

Jan 24, 2025, 1:05 PM EST - 2 months ago

Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

Jan 13, 2025, 8:05 AM EST - 2 months ago

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Dec 18, 2024, 8:05 AM EST - 3 months ago

HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT

Dec 3, 2024, 8:05 AM EST - 4 months ago

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Nov 21, 2024, 8:05 AM EST - 4 months ago

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Nov 11, 2024, 4:57 PM EST - 5 months ago

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points